Project Grant R41DA062292

Award Date 12/15/24
Completion Date 5/31/25
Dollars Obligated $307K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Cheney, WA 99004, USA
Similar Awards
This $591,848 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports the development of a smart speaker-based application to enhance housing stability and provide evidence-based support for individuals with substance use disorders (SUDs) living in supportive housing communities. The primary goal is to create a technology-based intervention that teaches residents CBT-informed skills and applies contingency...
This Project Grant award from the National Institute on Drug Abuse (NIDA), funded under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development and large-scale deployment of a digital product called "Research and Engagement on Substance Use Harnessing Awareness and Personalized Education (RESHAPE)." The $304,023 award to Evidation Health, Inc. aims to create a digital solution that addresses the health-related social needs (HRSN) impacting substance use...
This Project Grant award for $773,241, issued by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop an evidence base for strategies and interventions to improve health outcomes and reduce racial/ethnic disparities among people experiencing homelessness. The University of Colorado-Denver, the prime awardee, will employ a group model building approach to engage community stakeholders in developing agent-based simulation...
This $267,696 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) is funding the University of Massachusetts Lowell (UML) to create the PHIT-AR (Addiction Research) track within its existing Public Health Informatics and Technology (PHIT) program. The goal is to recruit and train a diverse group of motivated undergraduate students in data science skills to pursue doctoral training and careers in drug addiction research. Key...
The federal Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $569,971 to Prevention Strategies, LLC to design, evaluate, and optimize an online behavioral intervention to prevent and reduce substance use among high school seniors during their critical transition to young adulthood. The intervention targets social influences, a key driver of substance use, by using normative education to change norms around...
This $1,607,146 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and evaluation of a technology-based intervention to encourage protective behaviors against overdose among people who use drugs. The project, titled "Together Against Overdose: Community Developed Technology to Encourage Drug Checking, Distribution of Harm Reduction Supplies, and Linkage to Services," aims to...
This $755,298 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports research to identify features of negative and positive affect dynamics that predict return to substance use during community reintegration following residential treatment. The 5-year project (May 2024 - Feb 2029) will integrate real-time subjective data from ecological momentary assessment with physiological data from a wearable biosensor to...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $451,962 to Friends Research Institute, Inc. to address racial disparities in opioid overdose deaths among Black and Latinx people who use opioids. The key products and services to be delivered under this 3-year grant include: Adapting an evidence-supported cultural and structural humility (CSH) training into interactive video modules for peer recovery...
This federal Project Grant award of $375,000, provided by the U.S. Department of Health and Human Services' Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program, will fund the implementation of targeted strategies to provide substance use disorder treatment, harm reduction services, and peer recovery support services for people experiencing or at risk of...
This federal Project Grant award, totaling $2,214,862.00 and issued by the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs), supports a study to optimize the use of long-acting injectable (LAI) medications for opioid use disorder (MOUD) and HIV pre-exposure prophylaxis (PrEP) in carceral populations. The key products and services to be delivered under this grant include: Developing a protocol for delivering LAI PrEP and extended-release buprenorphine...

This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $306,678 to Hart3S - A Social Purpose Corporation to build and test the LEAPLINK digital training tool. The goal is to better serve people with lived experience of homelessness and substance use disorder, even after they move into housing.

The project aims to integrate community-based participatory and human-centered design principles to co-develop the LEAPLINK prototype with people with lived experience and a nonprofit agency that serves them. The LEAPLINK is envisioned as a learning management system, video-on-demand training, and synchronous consultation to help providers create a locally successful Life Enhancing Advocacy Program (LEAP) in their communities. This project will advance through usability testing and feasibility/acceptability assessment of the LEAPLINK prototype, laying the groundwork for a future randomized controlled trial to evaluate its effectiveness.

Generated 4/1/25, 3:58 AM